Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,809 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00073541 | A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer | completed | Phase 2 | 38 | EMD SeronoINDUSTRY | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00416533 |
| Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy |
| completed |
| Phase 2 |
| 47 |
| Wake Forest University Health SciencesOTHER |
| 0 |
| Jan 19, 2017 |
| clinicaltrials |
| NCT00450619 | 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT00559377 | FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT00872989 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 129 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 19, 2016 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | completed | Phase 2 | 40 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00659438 | Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer | completed | Phase 2 | 95 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01750398 | Bipolar Androgen-based Therapy for Prostate Cancer (BAT)(BAT) | completed | Phase 2 | 33 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT00179712 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00427999 | Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer(INV342) | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 21, 2016 | clinicaltrials |
| NCT00171808 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer(deFEND) | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00580970 | Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury | completed | Phase 2 | 73 | Virginia Commonwealth UniversityOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00744718 | Bevacizumab and Carboplatin for Patients With Ovarian Cancer | completed | Phase 2 | 73 | Vejle HospitalOTHER | 1 | Nov 16, 2016 | clinicaltrials |
| NCT00946309 | Effects of Sulforaphane on Normal Prostate Tissue(PHASE) | completed | Phase 1 / Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT00081159 | Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02017353 | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma | completed | Phase 2 | 7 | University Hospital, GasthuisbergOTHER | 1 | Oct 25, 2016 | clinicaltrials |
| NCT00776594 | Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | completed | Phase 2 | 102 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01558219 | Second-line Chemotherapy in Castration Resistant Prostate Cancer(ProstyII) | completed | Phase 2 | 60 | Tampere University HospitalOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT02002455 | Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI(Flucipro) | completed | Phase 2 | 26 | Turku University HospitalOTHER_GOV | 1 | Oct 21, 2016 | clinicaltrials |
| NCT00553878 | Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer(AVIAS) | completed | Phase 2 / Phase 3 | 100 | Canadian Urology Research ConsortiumOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02562729 | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer | completed | Phase 2 | 62 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00498797 | E3-Hormone Refractory Prostrate Cancer Taxotere Combination | completed | Phase 2 | 86 | SanofiINDUSTRY | 5 | Oct 7, 2016 | clinicaltrials |
| NCT01630018 | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | completed | Phase 2 | 141 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01076335 | Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT00852007 | A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1(MUC1) | completed | Phase 1 / Phase 2 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer(RADBEV) | completed | Phase 2 | 50 | University of PittsburghOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02523365 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01246440 | Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission | completed | Phase 2 | 39 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT01455493 | A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma | completed | Phase 2 | 56 | Genentech, Inc.INDUSTRY | 1 | Aug 11, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01325311 | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2016 | clinicaltrials |
| NCT01639625 | Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application | completed | Phase 2 | 18 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Aug 2, 2016 | clinicaltrials |
| NCT00216099 | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | 49 | Christopher Sweeney, MBBSOTHER | 1 | Jul 29, 2016 | clinicaltrials |
| NCT01511536 | Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | SanofiINDUSTRY | 3 | Jul 28, 2016 | clinicaltrials |
| NCT02499848 | Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer | completed | Phase 2 | 18 | Sophiris Bio CorpINDUSTRY | 1 | Jul 27, 2016 | clinicaltrials |
| NCT00196339 | A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients | completed | Phase 2 | 315 | Duramed ResearchINDUSTRY | 2 | Jul 22, 2016 | clinicaltrials |
| NCT00031746 | Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels | completed | Phase 2 | 26 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT00006359 | Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 63 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT00005810 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 40 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00091377 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 65 | MEI Pharma, Inc.INDUSTRY | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00005820 | Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 35 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00005828 | Green Tea Extract in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 54 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00006214 | Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate | completed | Phase 2 | 63 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 13, 2016 | clinicaltrials |
| NCT00031759 | Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia | completed | Phase 2 | 57 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00032006 | Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer | completed | Phase 2 | 48 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jan 20, 2017source: clinicaltrials